<DOC>
	<DOCNO>NCT01976182</DOCNO>
	<brief_summary>LGL leukemia represent rare subtype chronic T NK lymphoproliferative disorder . It indolent disease , main hematological autoimmune complication lead treatment 60 % patient . Investigators set University Hospital Rennes , database 300 patient LGL leukemia major French service support disease , publish 2010 large series patient world ( n = 229 ) . However , limited heterogeneity retrospective data collect , previously release , make difficult proposal consensual treatment option . If first second line treatment base use immunosuppression methotrexate , cyclophosphamide , cyclosporin A , molecule proven superiority others . Methotrexate cyclophosphamide mainly use first line . Invetigators literature data 100 patient treat either drug . Combining result series literature , invetigators estimate respective overall response rate ( RG ) complete response rate ( CR ) 55 % 30 % methotrexate , 60 % 50 % cyclophosphamide . Thus , four objective study : 1. compare respective efficacy methotrexate cyclophosphamide administer first-line therapy patient suffer T/NK LGL leukemia severe neutropenia neutropenia associate infection , and/or anemia require transfusion , and/or auto-immune associate disease 2. evaluate percentage patient refractory methotrexate cyclophosphamide second line treatment efficacious 3. explore , case non-response first-line therapy , efficacy ciclosporine A , comparison perform treatment administer first-line therapy 4. evaluate response rate accord phenotypic subtype LGL leukemia .</brief_summary>
	<brief_title>Prospective , Multicentric , Phase II Randomized Controlled Trial Two Parallel Groups Comparing Efficacy Two Immunosuppressive Drugs ( Methotrexate , Cyclophosphamide ) Large Granular Lymphocytes Leukemia</brief_title>
	<detailed_description>Large Granular Lymphocyte ( LGL ) leukemia clonal disorder involve tissue invasion marrow , spleen liver . Clinical presentation dominate recurrent infection associate neutropenia , anemia , splenomegaly , auto-immune disease , particularly rheumatoid arthritis . Both T cell NK cell subtypes LGL leukemia indolent disease consider chronic illness lead treatment 60 % patient . LGL leukemia display chronic clinical course . Recommendations regard therapy similar subtypes . Indications treatment include 1 ) severe neutropenia ( ANC &lt; 500 mm3 ) ; 2 ) neutropenia ( ANC &lt; 1500mm3 ) symptomatic recurrent infection ; 3 ) symptomatic transfusion-dependent anemia 4 ) associate autoimmune condition require therapy , often rheumatoid arthritis . There standard treatment patient LGL leukemia . The numerous case report publish provide consensus particular treatment . All six large series publish literature far ( collect data 40 patient ) retrospective . Immunosuppressive therapy remain foundation treatment include single three agent i.e . methotrexate , oral cyclophosphamide ciclosporin A . However prospective trial involve large number patient perform molecule proven superiority others . Invetigators set University Hospital Rennes , database 300 patient LGL leukemia major French service support disease , publish 2010 large series patient world ( n = 229 ) . However , limited heterogeneity retrospective data collect , previously release , make difficult proposal consensual treatment option . Combining result series literature , invetigators estimate overall response rate complete response rate 55 % 30 % methotrexate , 60 % 50 % cyclophosphamide , 55 % le 20 % ciclosporine A , respectively . Thus , four objective study : 1. compare respective efficacy methotrexate cyclophosphamide administer first-line therapy patient suffer T/NK LGL leukemia severe neutropenia neutropenia associate infection , and/or anemia require transfusion , and/or auto-immune associate disease 2. evaluate percentage patient refractory methotrexate cyclophosphamide second line treatment efficacious 3. explore , case non-response first-line therapy , efficacy ciclosporine A , comparison perform treatment administer first-line therapy 4. evaluate response rate accord phenotypic subtype LGL leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Common criterion LGL leukemia : diagnosis base chronic LGL peripheral blood expansion ( &gt; 0.5x109/L ) , usually last 6 month Specific criterion TLGL leukemia NKLGL lymphocytosis chronic NKLGL leukemia : Specific criterion TLGL leukemia : Expression LGL surface marker compatible activate Tcell ( commonly alphabeta+/CD3+/CD8+/CD57+ and/or CD16+ ) phenotype gammadelta+ T cell ; Clonal rearrangement TCRγ gene use PCR specific clonal Vβ expression use FCM . Specific criterion NKLGL lymphocytosis chronic NK LGL leukemia : Expression LGL surface marker compatible NK cell ( commonly CD3/CD8+/CD16+ and/or CD16+/CD56+ ) phenotype ; CD56+ CD16+ NK cell great 0.75x109/L ; The term chronic NKLGL lymphocytosis use patient chronic illness ( NB : patient massive tissue LGL infiltration spleen , liver bone marrow present aggressive clinical behavior consider aggressive NKLGL leukemia include ) . Age 18 year ECOG performance status 02 Life expectancy least 1 year Lack previous treatment ( except GCSF transfusion ) At least one indication treatment : Isolated severe neutropenia ( ANC &lt; 0.5x109/L ) neutropenia ( ANC &lt; 1.5x109/L ) two infection require antibiotic ; Anemia ( whatever underlie mechanism : pure red cell aplasia marrow infiltration ) require transfusion great 2 unit two month prior inclusion , symptomatic anemia ( hemoglobin &lt; 10g/dl ) impairment quality life ; Associated complication systemic disease autoimmune disease ( i.e . recurrent uveitis , cutaneous vasculitis , autoimmune hemolytic anemia , idiopathic thrombocytopenic purpura , rheumatoid arthritis resistant steroid and/or immunomodulator agent ( colchicin , disulone , hydrochloroquine ) ) justify treatment methotrexate cyclophosphamide Written inform consent Inability understand follow study procedure Prior concurrent malignancy within past 5 year except inactive nonmelanomatous skin cancer carcinoma situ cervix Other serious medical illness , hepatic , renal , cardiac , pulmonary , neurologic , metabolic disease would preclude patient 's ability tolerate methotrexate , cyclophosphamide , ciclosporine A Reactive LGL lymphocytosis ( i.e . viral infection ) ALAT/ASAT alkalin phosphatases &gt; 3 time normal value Creatinine clairance &lt; 50 ml/min Serologic evidence HIV , hepatitis C hepatitis B infection Non effective contraception Positive pregnancy test Nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>large granular lymphocyte leukemia</keyword>
	<keyword>immunosuppressive drug</keyword>
	<keyword>methotrexate</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>efficiency</keyword>
	<keyword>phase II randomize control trial</keyword>
</DOC>